Therapeutic plasma exchange combined with ribavirin to rescue critical SFTS patients
Fuente:
Wiley Open Access
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | Artículo Open Access |
| Publicado: |
Wiley
2024
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1867016702029463552 |
|---|---|
| author | Xuezhen Song Xiaojun Xu Xiaoning Ren Xiaoxuan Ruan Jinshuang Bo |
| author_facet | Xuezhen Song Xiaojun Xu Xiaoning Ren Xiaoxuan Ruan Jinshuang Bo Xuezhen Song Xiaojun Xu Xiaoning Ren Xiaoxuan Ruan Jinshuang Bo |
| collection | Wiley Open Access |
| contents | Therapeutic plasma exchange combined with ribavirin to rescue critical SFTS patients Xuezhen Song Xiaojun Xu Xiaoning Ren Xiaoxuan Ruan Jinshuang Bo Journal of Clinical Apheresis AbstractBackgroundSevere fever with thrombocytopenia syndrome (SFTS) is a zoonotic infectious disease caused by the severe fever with thrombocytopenia syndrome virus (SFTSV). Endemic in East Asia, SFTS is characterized by an exceptionally high mortality rate. Presently, there is no established treatment for SFTS, particularly for patients in critical condition. In this study, we collected and analyzed laboratory and clinical data from 92 critically ill patients with SFTS treated at Weihai Municipal Hospital between 2019 and 2022. We hope that our study will provide some hints for the treatment of critically ill patients with SFTS.MethodsA total of 92 critically ill patients with SFTS were included in this study. Of these patients, 45 received treatment with therapeutic plasma exchange (TPE) and ribavirin (referred to as the TPE group), while the remaining patients received only ribavirin (referred to as the non‐TPE group). Clinical and laboratory parameters were analyzed retrospectively.ResultsThe results showed significant improvements in multiple laboratory parameters following treatment with TPE and ribavirin, including white blood cell and neutrophil count, lactate dehydrogenase, creatine kinase isoenzyme‐MB, prothrombin time, activated partial thromboplastin time, D‐Dimer, serum sodium and copies of virus genomes. The combination of TPE with ribavirin demonstrated a significant reduction in mortality rates, with a mortality rate of 20.0% in the TPE group compared to 40.4% in the non‐TPE group (P = 0.033).ConclusionsOur findings suggest that critically ill patients with SFTS who received TPE and ribavirin experienced improvements in both clinical and laboratory parameters. These results indicate that TPE combined with ribavirin may represent a promising novel therapeutic approach for managing critically ill patients with SFTS. However, comparative studies of large sample size or randomized clinical trials are warranted to confirm the effectiveness of this combination therapy in the treatment of severe SFTS cases. 10.1002/jca.22131 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| doi_str_mv | 10.1002/jca.22131 |
| format | Artículo Open Access |
| id | wiley_oa_10_1002_jca_22131 |
| institution | Wiley Open Access |
| license_str_mv | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| publishDate | 2024 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Therapeutic plasma exchange combined with ribavirin to rescue critical SFTS patients Xuezhen Song Xiaojun Xu Xiaoning Ren Xiaoxuan Ruan Jinshuang Bo Journal of Clinical Apheresis Therapeutic plasma exchange combined with ribavirin to rescue critical SFTS patients Xuezhen Song Xiaojun Xu Xiaoning Ren Xiaoxuan Ruan Jinshuang Bo Journal of Clinical Apheresis AbstractBackgroundSevere fever with thrombocytopenia syndrome (SFTS) is a zoonotic infectious disease caused by the severe fever with thrombocytopenia syndrome virus (SFTSV). Endemic in East Asia, SFTS is characterized by an exceptionally high mortality rate. Presently, there is no established treatment for SFTS, particularly for patients in critical condition. In this study, we collected and analyzed laboratory and clinical data from 92 critically ill patients with SFTS treated at Weihai Municipal Hospital between 2019 and 2022. We hope that our study will provide some hints for the treatment of critically ill patients with SFTS.MethodsA total of 92 critically ill patients with SFTS were included in this study. Of these patients, 45 received treatment with therapeutic plasma exchange (TPE) and ribavirin (referred to as the TPE group), while the remaining patients received only ribavirin (referred to as the non‐TPE group). Clinical and laboratory parameters were analyzed retrospectively.ResultsThe results showed significant improvements in multiple laboratory parameters following treatment with TPE and ribavirin, including white blood cell and neutrophil count, lactate dehydrogenase, creatine kinase isoenzyme‐MB, prothrombin time, activated partial thromboplastin time, D‐Dimer, serum sodium and copies of virus genomes. The combination of TPE with ribavirin demonstrated a significant reduction in mortality rates, with a mortality rate of 20.0% in the TPE group compared to 40.4% in the non‐TPE group (P = 0.033).ConclusionsOur findings suggest that critically ill patients with SFTS who received TPE and ribavirin experienced improvements in both clinical and laboratory parameters. These results indicate that TPE combined with ribavirin may represent a promising novel therapeutic approach for managing critically ill patients with SFTS. However, comparative studies of large sample size or randomized clinical trials are warranted to confirm the effectiveness of this combination therapy in the treatment of severe SFTS cases. 10.1002/jca.22131 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| title | Therapeutic plasma exchange combined with ribavirin to rescue critical SFTS patients |
| topic | Journal of Clinical Apheresis |
| url | https://onlinelibrary.wiley.com/doi/10.1002/jca.22131 |